Thomas Rachel, Patel Hamish, Scott Joshua
Internal Medicine, Wright State University Boonshoft School of Medicine, Dayton, USA.
Rheumatology, Brooke Army Medical Center, Fort Sam Houston, USA.
Cureus. 2021 Apr 9;13(4):e14387. doi: 10.7759/cureus.14387.
Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literature exists regarding the treatment of patients with pre-existing myositis. We describe a case of myositis flare after initiation of nivolumab for metastatic melanoma in a patient who had previously achieved remission of dermatomyositis.
免疫检查点抑制剂（ICI）药物在多种恶性肿瘤的治疗中得到了更广泛的应用。这些疗法会引发一系列独特的免疫相关不良事件（irAE）。ICI引发的风湿性irAE在各种病例报告中均有描述；然而，关于已有肌炎患者治疗的文献却很有限。我们描述了一例在接受纳武单抗治疗转移性黑色素瘤后发生肌炎发作的病例，该患者此前已缓解的皮肌炎。
